IL277888B2 - Methods for reducing drug target interference in anti-drug antibody (ADA) immunoassays - Google Patents
Methods for reducing drug target interference in anti-drug antibody (ADA) immunoassaysInfo
- Publication number
- IL277888B2 IL277888B2 IL277888A IL27788820A IL277888B2 IL 277888 B2 IL277888 B2 IL 277888B2 IL 277888 A IL277888 A IL 277888A IL 27788820 A IL27788820 A IL 27788820A IL 277888 B2 IL277888 B2 IL 277888B2
- Authority
- IL
- Israel
- Prior art keywords
- drug
- drug target
- label
- antibody
- ada
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696016P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/040950 WO2020014194A1 (en) | 2018-07-10 | 2019-07-09 | Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277888A IL277888A (en) | 2020-11-30 |
| IL277888B1 IL277888B1 (en) | 2024-12-01 |
| IL277888B2 true IL277888B2 (en) | 2025-04-01 |
Family
ID=67544324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277888A IL277888B2 (en) | 2018-07-10 | 2019-07-09 | Methods for reducing drug target interference in anti-drug antibody (ADA) immunoassays |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12055551B2 (enExample) |
| EP (1) | EP3821255B1 (enExample) |
| JP (3) | JP7493459B2 (enExample) |
| KR (1) | KR102754704B1 (enExample) |
| CN (1) | CN112384808B (enExample) |
| AU (1) | AU2019301614B2 (enExample) |
| BR (1) | BR112020022912A2 (enExample) |
| EA (1) | EA202190237A1 (enExample) |
| ES (1) | ES2993989T3 (enExample) |
| IL (1) | IL277888B2 (enExample) |
| MA (1) | MA53130A (enExample) |
| MX (1) | MX2021000331A (enExample) |
| MY (1) | MY207418A (enExample) |
| SG (1) | SG11202011283TA (enExample) |
| WO (1) | WO2020014194A1 (enExample) |
| ZA (1) | ZA202006409B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
| CN114264814B (zh) * | 2021-12-30 | 2025-03-14 | 苏州和锐生物科技有限公司 | 一种pd-1生物制剂的抗体检测试剂盒及制备方法 |
| CN114324894A (zh) * | 2021-12-31 | 2022-04-12 | 军科正源（北京）药物研究有限责任公司 | 一种检测贝伐珠单抗抗药性抗体的新型分析方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| WO2023204378A1 (ko) * | 2022-04-19 | 2023-10-26 | 의료법인 성광의료재단 | 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법 |
| CN119790065A (zh) * | 2022-08-24 | 2025-04-08 | 美国安进公司 | 抗药物抗体测定 |
| CN115586337A (zh) * | 2022-09-14 | 2023-01-10 | 杭州赛基生物科技有限公司 | 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法 |
| CN120239821A (zh) * | 2022-09-23 | 2025-07-01 | 默沙东有限责任公司 | 中和抗体测定方法 |
| CN115575468B (zh) * | 2022-09-30 | 2025-08-26 | 华润生物医药有限公司 | 一种检测抗重组人GLP-1-Fc融合蛋白抗体的方法 |
| CN115856322A (zh) * | 2022-12-23 | 2023-03-28 | 同昕生物技术（北京）有限公司 | 用于抗奥马株单抗药物抗体检测的试剂及其应用 |
| CN117805382B (zh) * | 2024-02-28 | 2024-05-03 | 军科正源（北京）药物研究有限责任公司 | 检测抗利妥昔单抗中和抗体的方法 |
| WO2025224166A1 (en) * | 2024-04-23 | 2025-10-30 | F. Hoffmann-La Roche Ag | Anti-drug antibody assays |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856469A (en) * | 1973-01-02 | 1974-12-24 | Syva Corp | Interferant removal from amphetamine immunoassay |
| JPS55145690A (en) | 1979-05-04 | 1980-11-13 | Toyama Chem Co Ltd | Novel penicillin and cephalosporin, and its salt |
| JPS6454356A (en) * | 1987-08-26 | 1989-03-01 | Meidensha Electric Mfg Co Ltd | Method for suppressing non-specific adsorption of antibody to solid phase antigen |
| JPH02138872A (ja) | 1988-11-18 | 1990-05-28 | Asahi Chem Ind Co Ltd | 癌関連物質のための免疫測定方法 |
| WO2005031353A1 (ja) | 2003-09-26 | 2005-04-07 | Matsushita Electric Industrial Co., Ltd. | 免疫反応測定方法、ならびにそれに用いる試薬、キット、及び光学セル |
| EP2142925A1 (en) | 2007-05-07 | 2010-01-13 | Wyeth a Corporation of the State of Delaware | Elimination of interference in immunoassays caused by anti-carbohydrate antibodies |
| WO2009022001A1 (en) * | 2007-08-16 | 2009-02-19 | Novartis Ag | Improvement of drug tolerance in immunogenicity testing |
| CA3141978A1 (en) * | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| JP6563910B2 (ja) | 2013-07-04 | 2019-08-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ |
| EP4137816B1 (en) | 2014-02-11 | 2025-03-19 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| WO2017096262A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| US20190145985A1 (en) | 2017-11-10 | 2019-05-16 | BioAgilytix Labs, LLC | Method for eliminating target interference |
| JP7161534B2 (ja) | 2017-11-29 | 2022-10-26 | エフ．ホフマン－ラ ロシュ アーゲー | 標的による干渉が抑制された抗薬物抗体アッセイ |
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
-
2019
- 2019-07-09 BR BR112020022912-1A patent/BR112020022912A2/pt unknown
- 2019-07-09 JP JP2020564556A patent/JP7493459B2/ja active Active
- 2019-07-09 US US16/506,379 patent/US12055551B2/en active Active
- 2019-07-09 WO PCT/US2019/040950 patent/WO2020014194A1/en not_active Ceased
- 2019-07-09 AU AU2019301614A patent/AU2019301614B2/en active Active
- 2019-07-09 KR KR1020207033049A patent/KR102754704B1/ko active Active
- 2019-07-09 EP EP19749872.8A patent/EP3821255B1/en active Active
- 2019-07-09 MX MX2021000331A patent/MX2021000331A/es unknown
- 2019-07-09 MA MA053130A patent/MA53130A/fr unknown
- 2019-07-09 MY MYPI2020005155A patent/MY207418A/en unknown
- 2019-07-09 CN CN201980046236.XA patent/CN112384808B/zh active Active
- 2019-07-09 IL IL277888A patent/IL277888B2/en unknown
- 2019-07-09 EA EA202190237A patent/EA202190237A1/ru unknown
- 2019-07-09 SG SG11202011283TA patent/SG11202011283TA/en unknown
- 2019-07-09 ES ES19749872T patent/ES2993989T3/es active Active
-
2020
- 2020-10-15 ZA ZA2020/06409A patent/ZA202006409B/en unknown
-
2024
- 2024-02-20 JP JP2024023599A patent/JP2024045646A/ja active Pending
- 2024-07-03 US US18/763,265 patent/US20240353423A1/en active Pending
-
2025
- 2025-10-23 JP JP2025179025A patent/JP2026012856A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| DAI S. ET AL.,, DEVELOPMENT OF A METHOD THAT ELIMINATES FALSE-POSITIVE RESULTS DUE TO NERVE GROWTH FACTOR INTERFERENCE IN THE ASSESSMENT OF FULRANUMAB IMMUNOGENICITY, 3 May 2014 (2014-05-03) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7493459B2 (ja) | 2024-05-31 |
| US12055551B2 (en) | 2024-08-06 |
| IL277888A (en) | 2020-11-30 |
| JP2021531448A (ja) | 2021-11-18 |
| KR102754704B1 (ko) | 2025-01-20 |
| AU2019301614A1 (en) | 2020-10-22 |
| ES2993989T3 (en) | 2025-01-15 |
| ZA202006409B (en) | 2025-07-30 |
| KR20210031854A (ko) | 2021-03-23 |
| EP3821255A1 (en) | 2021-05-19 |
| CA3098206A1 (en) | 2020-01-16 |
| MA53130A (fr) | 2021-05-19 |
| EA202190237A1 (ru) | 2021-04-15 |
| JP2026012856A (ja) | 2026-01-27 |
| CN112384808B (zh) | 2024-10-11 |
| US20240353423A1 (en) | 2024-10-24 |
| MX2021000331A (es) | 2021-03-25 |
| WO2020014194A1 (en) | 2020-01-16 |
| BR112020022912A2 (pt) | 2021-02-23 |
| CN112384808A (zh) | 2021-02-19 |
| JP2024045646A (ja) | 2024-04-02 |
| MY207418A (en) | 2025-02-26 |
| SG11202011283TA (en) | 2020-12-30 |
| EP3821255B1 (en) | 2024-08-28 |
| IL277888B1 (en) | 2024-12-01 |
| AU2019301614B2 (en) | 2025-11-20 |
| US20200018770A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277888B1 (en) | Methods for reducing drug target interference in anti-drug antibody (ADA) immunoassays | |
| Tadesse et al. | Submicroscopic carriage of Plasmodium falciparum and Plasmodium vivax in a low endemic area in Ethiopia where no parasitaemia was detected by microscopy or rapid diagnostic test | |
| Reverté et al. | Detection of tetrodotoxins in puffer fish by a self-assembled monolayer-based immunoassay and comparison with surface plasmon resonance, LC-MS/MS, and mouse bioassay | |
| Xiulan et al. | Development of an immunochromatographic assay for detection of aflatoxin B1 in foods | |
| Zhou et al. | Colloidal gold probe-based immunochromatographic assay for the rapid detection of brevetoxins in fishery product samples | |
| Yang et al. | Quantitative determination of major capsaicinoids in serum by ELISA and time-resolved fluorescent immunoassay based on monoclonal antibodies | |
| JP2021531448A5 (enExample) | ||
| Sahimin et al. | Migrant workers in Malaysia: current implications of sociodemographic and environmental characteristics in the transmission of intestinal parasitic infections | |
| Yao et al. | Colloidal gold‐McAb probe‐based rapid immunoassay strip for simultaneous detection of fumonisins in maize | |
| Van Coillie et al. | Development of an indirect competitive ELISA for flumequine residues in raw milk using chicken egg yolk antibodies | |
| Wu et al. | Development of an immunochromatographic test strip for rapid simultaneous detection of enrofloxacin and ofloxacin in tissue of chicken muscle and pork | |
| O'Kennedy et al. | Don't blame it all on antibodies–The need for exhaustive characterisation, appropriate handling, and addressing the issues that affect specificity | |
| Širović et al. | Using passive acoustics to model blue whale habitat off the Western Antarctic Peninsula | |
| Dolka et al. | Retrospective study and immunohistochemical analysis of canine mammary sarcomas | |
| MX2008000277A (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente. | |
| Lehman et al. | Epidemiology of malaria using LED fluorescence microscopy among schoolchildren in Douala, Cameroon | |
| Liu et al. | Development of a broad-specific competitive ELISA for first-generation cephalosporin antibiotics in animal-derived foods samples | |
| Galatas et al. | Field performance of ultrasensitive and conventional malaria rapid diagnostic tests in southern Mozambique | |
| Na et al. | A highly sensitive monoclonal antibody− based paper sensor for simultaneously detecting valnemulin and tiamulin in porcine liver | |
| Kyei-Baafour et al. | Suitability of IgG responses to multiple Plasmodium falciparum antigens as markers of transmission intensity and pattern | |
| Wang et al. | Rapid enzyme-linked immunosorbent assay and colloidal gold immunoassay for assessing okadaic acid and its derivatives in shellfish | |
| Becker-Merok et al. | Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis | |
| Kranthi et al. | Development of a colloidal-gold based lateral-flow immunoassay kit for ‘quality-control’assessment of pyrethroid and endosulfan formulations in a novel single strip format | |
| Urusov et al. | Indirect labeling of antibodies as a universal approach to increase sensitivity of lateral flow tests: A case study for mycotoxins detection | |
| Chen et al. | Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH |